Syntach AB (STO: SSAB-A) announced on Wednesday that its Syntach Cardiac Support system (Syntach CS) has been selected for an oral presentation in the Best Innovation Competition to be held during the CRT 2023 annual meeting, to be held at the Omni Shoreham Hotel in Washington DC from 25 to 28 February 2023.

Cardiovascular Research Technologies (CRT) is an educational forum on new cardiovascular technology and procedures for physicians and health-care professionals.

The company said that its novel Cardiac Support System will be presented by Monica Tocchi, MD, PhD, and the CEO and Founder of Meditrial USA Inc (Meditrial) in a talk titled "Minimally Invasive Fully Implantable Cardiac Support Technology To Restore Cardiac Function In Heart Failure Patients".

Syntach's Cardiac Support System is a novel device and treatment method developed to enhance the natural movement designed to restore the heart's natural pump by acting on the motion of the mitral valve plane during the cardiac cycle, making each heartbeat more effective. This technology does not require open heart surgery and is powered by an implanted battery, avoiding a drive line through the skin and many of the negative side effects associated with available assist devices. The company added that its technology also qualifies for the CRT 2023 Top Innovation Award.

Based in Lund, Sweden, Syntach AB develops cardiac support systems as well as mitral valve intervention systems in cooperation with several academic research centres.